AKESO: VOLUNTARY ANNOUNCEMENT - THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION ACCEPTED THE SUPPLEMENTAL NEW DRUG APPLICATION FOR CADONILIMAB (PD-1/CTLA-4) AS FIRST-LINE TREATMENT FOR CERVICAL CANCER
AKESO: Notification Letter and Reply Form to Non-registered Shareholders - Arrangement of Electronic Dissemination of Corporate Communications
AKESO: Notification Letter and Reply Form to Registered Shareholders - Arrangement of Electronic Dissemination of Corporate Communications
AKESO: Monthly Return of Equity Issuer on Movements in Securities for the Month ended 31 March 2024
AKESO: Next Day Disclosure Return
AKESO: COMPLETION OF PLACING OF NEW SHARES UNDER GENERAL MANDATE
AKESO: PLACING OF NEW SHARES UNDER GENERAL MANDATE
AKESO: ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2023
AKESO: DATE OF BOARD MEETING
AKESO: Monthly Return of Equity Issuer on Movements in Securities for the Month ended 29 February 2024
AKESO: INSIDE INFORMATION ANNOUNCEMENT POSITIVE PROFIT ALERT
AKESO: CONNECTED TRANSACTION FURTHER INFORMATION IN RELATION TO ACQUISITION OF EQUITY INTEREST IN AD PHARMACEUTICALS
AKESO: CONNECTED TRANSACTION IN RELATION TO ACQUISITION OF EQUITY INTEREST IN AD PHARMACEUTICALS
AKESO: Monthly Return of Equity Issuer on Movements in Securities for the Month ended 31 January 2024
AKESO: Monthly Return of Equity Issuer on Movements in Securities for the Month ended 31 December 2023
AKESO: VOLUNTARY ANNOUNCEMENT - NMPA ACCEPTED THE SUPPLEMENTAL NEW DRUG APPLICATION FOR CADONILIMAB (PD-1/CTLA-4) IN COMBINATION WITH CHEMOTHERAPY AS FIRST-LINE TREATMENT FOR GASTRIC CANCER
AKESO: Monthly Return of Equity Issuer on Movements in Securities for the Month ended 30 November 2023
AKESO: VOLUNTARY ANNOUNCEMENT - AK104-303, A PHASE III TRIAL OF CADONILIMAB REACHED PROGRESSION-FREE-SURVIVAL (PFS) PRIMARY ENDPOINT AT INTERIM ANALYSIS FOR FIRST LINE TREATMENT OF CERVICAL CANCER
AKESO: VOLUNTARY ANNOUNCEMENT - AK104-302, A PHASE III TRIAL OF CADONILIMAB IN COMBINATION WITH CHEMOTHERAPY AS FIRST LINE TREATMENT FOR GASTRIC OR GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA (GC/GEJC) REACHED PRIMARY ENDPOINT OF OVERALL SURVIVAL (OS) AT INT
AKESO: Monthly Return of Equity Issuer on Movements in Securities for the Month ended 31 October 2023
No Data